Profile

Leslie Renee Ellis, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

108 Ratings
15 Comments
 

Leslie Renee Ellis, M.D.

Associate Professor,

Clinical Interests

Acute and Chronic Leukemia, Chronic Leukemias, Hematologic Malignancies, Leukemia

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., Duke University, 1991
  • M.D., University of North Carolina-Chapel Hill, 2000
  • Internship, Internal Medicine, Univ Hosp (U Of Michigan), 2001
  • Residency, Internal Medicine, U Michigan Affil Hosps, 2003
  • Fellowship, Hematology And Oncology, Cornell University, 2006

Board Certifications

  • American Board of Internal Medicine, Medical Oncology

NPI Number

  • 1790861128
Leslie Renee Ellis, M.D.

Doctor Rating

4.6 out of 5

108 Ratings
15 Comments
 

Leslie Renee Ellis, M.D.

Associate Professor, Hematology & Oncology

Research Interests

Leukemia, Myeloid, Acute; Lysophospholipase; Glycoproteins; Bone Marrow; Trans-Activators
More »

Contact Information

Academic: 336-716-4759 | Department: 336-716-4464

Recent Publications

High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.. Leuk Res. 2015;39(9):945-949.

Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. J Clin Oncol. 2015;33(15 Suppl):7015.

The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL.. Blood. 2015;126(23):2556.

Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S.. Blood. 2015;126(23):2102.

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T.. Ann Hematol. 2014;93(1):47-55.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2014;20(20):5255-5264.

Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic. Jordan JH, D'Agostino RB Jr, Hamilton CA, Vasu S, Hall ME, Kitzman DW, Thohan V, Lawrence JA, Ellis LR, Lash TL, Hundley WG.. Circ Cardiovasc Imaging. 2014;7(6):872-879.

The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL.. Blood. 2014;124(21):3744.

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL.. Blood. 2013;121(21):4287-4294.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG.. JACC Cardiovasc Imaging. 2013;6(8):877-885.

Integrating the caregiver perspective: an interprofessional opportunity [commentary]. Bailey J, Currin D, Ellis L, Hite RD.. Med Educ. 2013;47(11):1137-1138.

Pathologic atrophy of the left ventricular myocardium early after receipt of anthracycline-based chemotherapy [abstract]. Jordan JH, Morgan TM, Ellis LR, Lawrence J, Hall ME, Castellino SM, Hamilton CA, Torti FM, Vasu S, D'Agostino RB, Hundley WG.. Circulation. 2013;128(22 Suppl):A17537.

Acute myeloid leukemia with Charcot-Leyden crystals. Manny JS, Ellis LR.. Blood. 2012;120(3):503.

The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL.. J Am Geriatr Soc. 2011;59(10):1837-1846.

A single institution analysis of incidence of recurrent chromosomal abnormalities in adult ALL patients according to race, gender, and age [abstract]. Chiou V, Tiegs J, Isom S, Pettenati MJ, Lyerly S, Ellis LR, Pardee T, Dmitriy B, Powell BL, Levitan DA.. Blood. 2011;118(21):4869.

Aortic stiffness increases upon receipt of anthracycline chemotherapy. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. J Clin Oncol. 2010;28(1):166-172.

Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Klepin HD, Tooze JA, Geiger AM, Kritchevsky S, Williamson J, Ellis LR, Levitan D, Pardee T, Isom S, Powell BL.. Blood. 2010;116(21):653-654.

Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W.. Circulation. 2010;122(21 Suppl):A12766.

Feasibility of inpatient geriatric assessment for older adults with acute myelogenous leukemia [abstract]. Klepin HD, Ellis LR, Levitan D, Powell BL.. J Am Geriatr Soc. 2009;57(Suppl 1):S155.

Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. Circulation. 2009;120(18 Suppl):S299.

Inpatient geriatric assessment detects impairment among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Klepin HD, Geiger AM, Williamson J, Kritchevsky S, Tooze JA, Ellis LR, Levitan D, Isom S, Powell BL.. Blood. 2009;114(22):570-571.

High dose cytarabine and clofarabine (HiDAC-->CLOF) in relapsed or refractory acute myeloid leukemia, a phase 2 trial [abstract]. Powell B, D'Agostino R Jr, Levitan D, Ellis LR, Lyerly S, Skiles M, Manuel M, Harrelson R, Kimbrough C, Hurd DD.. Blood. 2008;112(11):676.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Acute and Chronic Leukemia, Chronic Leukemias, Hematologic Malignancies, Leukemia
Leslie Renee Ellis, M.D.

Leslie Renee Ellis, M.D.

Associate Professor, Hematology & Oncology

Doctor Rating

4.6 out of 5

Leslie Renee Ellis, M.D.108 Ratings
15 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.7
CP spoke using clear language
4.7
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.8
Wait time at clinic
3.6



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

7/29/2016

Excellent.

7/21/2016

*Dr. Ellis is always friendly, kind and professional.

6/1/2016

Dr. Leslie Ellis has been a GOD send to us over the last 3 plus years. if you have to have cancer, you would pray for a doctor like her.

4/29/2016

*Dr. Ellis is the best! A perfect model of patient-centered care. I would not change doctors for any reason; even if you didn't charge me for visits.

4/29/2016

Friendly.

4/27/2016

*Dr. Ellis was excellent in every way. I am blessed to have her as my physician.

3/28/2016

Information and directions always great.

2/21/2016

My providers have always been very accommodating in listening to my concerns. I think I have a great team that is helping me fight this battle. Aside, from the other small issues, I really appreciate all of their help in saving my life.

2/16/2016

Dr Ellis is without a doubt the best; I take great comfort that she is my physician.

2/9/2016

I cannot believe the difference in Dr. Ellis and my previous hematologist at Emory/Winship Cancer Institute. Dr Ellis and her PA provided me with more information (in layman's terms) than I have gleaned in 4.5 years of having CLL.

12/16/2015

I've just started seeing Dr. Ellis, after seeing Dr. Swift more than a year ago I was referred to another Dr. who did not seem to care and was did not give me a comfort level I wanted. When Dr. Hix said I needed to see someone I agreed as long as it wasn't Dr. I had seen earlier. Dr. Ellis knew my history when she walked in and did not need me to tell her things that she could find in my chart. She has been very caring and helpful.

11/24/2015

Excellent.

11/6/2015

*Dr. Ellis is not only a most highly regarded subject-matter expert on my disorder, but she's friendly & easy to talk to. What an exceptional provider she is!

10/21/2015

So thankful for the staff.

9/30/2015

I am so fortunate to have been referred to Dr. Ellis for the management of my condition. She provides exceptional care, involves me in decision making and it is a pleasure to meet with her.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.